ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.090
-0.020 (-1.80%)
At close: Jun 18, 2026, 4:00 PM EDT
1.110
+0.020 (1.83%)
After-hours: Jun 18, 2026, 7:10 PM EDT
ADC Therapeutics Revenue
ADC Therapeutics had revenue of $20.85M in the quarter ending March 31, 2026, a decrease of -9.47%. This brings the company's revenue in the last twelve months to $79.18M, up 4.43% year-over-year. In the year 2025, ADC Therapeutics had annual revenue of $81.36M with 14.85% growth.
Revenue (ttm)
$79.18M
Revenue Growth
+4.43%
P/S Ratio
1.75
Revenue / Employee
$410,233
Employees
193
Market Cap
138.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 81.36M | 10.52M | 14.85% |
| Dec 31, 2024 | 70.84M | 1.28M | 1.84% |
| Dec 31, 2023 | 69.56M | -140.35M | -66.86% |
| Dec 31, 2022 | 209.91M | 175.99M | 518.89% |
| Dec 31, 2021 | 33.92M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Spero Therapeutics | 61.19M |
| Pyxis Oncology | 13.86M |
| NRx Pharmaceuticals | 2.29M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
| NeOnc Technologies Holdings | 39.99K |
| Genelux | 8.00K |
| Fractyl Health | 3.00K |
ADCT News
- 13 days ago - ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 17 days ago - ADC Therapeutics price target lowered to $5 from $8 at Stephens - TheFly
- 17 days ago - ADC Therapeutics plunges after patient deaths in blood cancer drug trial - Reuters
- 17 days ago - ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital - TheFly
- 17 days ago - ADC Therapeutics Transcript: Study result - Transcripts
- 17 days ago - ADC Therapeutics Slides: Study result - Filings
- 17 days ago - ADC Therapeutics Press release: Study result - Filings
- 17 days ago - ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL - TheFly